AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33580636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol, 50,000 IU/dose)
Number of subjects: 150
Study 33580636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 35235142 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text‐delivered scheduled gradual smoking reduction (SGR) program plus support texts
Number of subjects: 314
Study 35235142 — intervention group
Group type: COMPARATOR
Intervention: Support messages only
Number of subjects: 314
Study 34520679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in overdose events by peer responders
Number of subjects: 61
Study 34520679 — intervention group
Group type: COMPARATOR
Intervention: Previous intervention efforts
Number of subjects: 61
Study 32069236 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-ω3 (DO3)
Number of subjects: 180
Study 32069236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DP)
Number of subjects: 180
Study 32069236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional analysis
Number of subjects: 180
Study 35647977 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light (n = 55)
Number of subjects: 100
Study 35647977 — intervention group
Group type: COMPARATOR
Intervention: Yellow light (n = 45)
Number of subjects: 100
Study 32677987 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborating Across Systems for Program Implementation (CASPI) tool
Number of subjects: 17
Study 32677987 — intervention group
Group type: EXPERIMENTAL
Intervention: CASPI tool
Number of subjects: 17
Study 34791499 — intervention group
Group type: EXPERIMENTAL
Intervention: MA health coaching intervention
Number of subjects: 0
Study 34791499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33663862 — intervention group
Group type: EXPERIMENTAL
Intervention: LP4
Number of subjects: 51
Study 33663862 — intervention group
Group type: EXPERIMENTAL
Intervention: LP8
Number of subjects: 51
Study 33663862 — intervention group
Group type: COMPARATOR
Intervention: LP0
Number of subjects: 51
Study 32409982 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg CBD
Number of subjects: 24
Study 32409982 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg CBD
Number of subjects: 24
Study 32409982 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/kg CBD
Number of subjects: 24
Study 32409982 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (all doses)
Number of subjects: 24
Study 32409982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34859604 — intervention group
Group type: EXPERIMENTAL
Intervention: High social status position (experimental manipulation)
Number of subjects: 133
Study 34859604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low social status position (experimental manipulation)
Number of subjects: 133
Study 34859604 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying as low subjective social status (SSS)
Number of subjects: 133
Study 34130026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MedDiet)
Number of subjects: 44
Study 34130026 — intervention group
Group type: COMPARATOR
Intervention: Non MedDiet plus nuts (50 g/day)
Number of subjects: 44
Study 33906126 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA) - 3 ml inhalation solution containing 0.03% HA, self-administered twice daily
Number of subjects: 27
Study 33906126 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA)
Number of subjects: 27
Study 33906126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 33412023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunable cross‐Kerr‐type ZZ interaction with a flux‐tunable coupler element, performing a conditional phase CZ gate.
Number of subjects: 0
Study 33482134 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 116
Study 32434470 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 90
Study 32434470 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC®(D)
Number of subjects: 90
Study 32434470 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 36093393 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical‐nursing integrated nursing group (study group)
Number of subjects: 0
Study 36093393 — intervention group
Group type: COMPARATOR
Intervention: General nursing group (control group)
Number of subjects: 0
Study 33271178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/mL dexamethasone
Number of subjects: 117
Study 33271178 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/mL diclofenac sodium
Number of subjects: 117
Study 33271178 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 117
Study 35286282 — intervention group
Group type: EXPERIMENTAL
Intervention: CEAA supplementation (oral, twice daily for 2 weeks)
Number of subjects: 400
Study 35286282 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition (control group)
Number of subjects: 400
Study 35773443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intensive lifestyle modification program
Number of subjects: 320
Study 35773443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 33103727 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-based prediction models for cognitive and emotional test scores in early-stage idiopathic PD
Number of subjects: 688
Study 33103727 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 688
Study 32847919 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols published after the SPIRIT statement (2013)
Number of subjects: 300
Study 32847919 — intervention group
Group type: COMPARATOR
Intervention: Protocols published before the SPIRIT statement (2013)
Number of subjects: 300
Study 32847919 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement since the SPIRIT statement
Number of subjects: 300
Study 32847919 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual checklist items reporting
Number of subjects: 300
Study 35383071 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac 0.5 mg/kg + IV morphine placebo
Number of subjects: 100
Study 35383071 — intervention group
Group type: COMPARATOR
Intervention: IV morphine 0.1 mg/kg + IV ketorolac placebo
Number of subjects: 100
Study 34106990 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein guided antibiotherapy with levofloxacin
Number of subjects: 0
Study 34106990 — intervention group
Group type: COMPARATOR
Intervention: 2-day antibiotherapy with levofloxacin
Number of subjects: 0
Study 32170789 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg lycopene
Number of subjects: 720
Study 32170789 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg lycopene
Number of subjects: 720
Study 32170789 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg lycopene
Number of subjects: 720
Study 32170789 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg lycopene (control group)
Number of subjects: 720
Study 35061634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ISBPB with ICPB (BC)
Number of subjects: 40
Study 35061634 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided CPB with ICPB (CC)
Number of subjects: 40
Study 33451925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 200
Study 33451925 — intervention group
Group type: COMPARATOR
Intervention: Modified Balloon (MB)
Number of subjects: 200
Study 32474612 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for zone 1 fractures
Number of subjects: 1239
Study 32474612 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment for zone 1 fractures
Number of subjects: 1239
Study 32474612 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for Jones' (zone 2) fractures
Number of subjects: 1239
Study 32474612 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment for Jones' (zone 2) fractures
Number of subjects: 1239
Study 32474612 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal diaphyseal (zone 3) fractures
Number of subjects: 1239
Study 32618838 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive vagus nerve stimulation (nVNS)
Number of subjects: 0
Study 32618838 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 33464986 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment model for high school students with ASD
Number of subjects: 544
Study 33464986 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and teacher reports of school support intensity
Number of subjects: 544
Study 34528462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse juries (ambiguous evidence)
Number of subjects: 802
Study 34528462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse juries (wealth and power conditions)
Number of subjects: 802
Study 34528462 — intervention group
Group type: COMPARATOR
Intervention: Nondiverse juries (ambiguous evidence)
Number of subjects: 802
Study 34528462 — intervention group
Group type: COMPARATOR
Intervention: Nondiverse juries (wealth and power conditions)
Number of subjects: 802
Study 32023526 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone mobile app
Number of subjects: 181
Study 32023526 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study 34171159 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 176
Study 34483022 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg QS-21-containing C difficile vaccine
Number of subjects: 0
Study 34483022 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 or 200 µg unadjuvanted C difficile vaccine formulation
Number of subjects: 0
Study 34483022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35169011 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine preventive medication without switching of the overused medication
Number of subjects: 720
Study 35169011 — intervention group
Group type: COMPARATOR
Intervention: Migraine preventive medication with switching from the overused medication
Number of subjects: 720
Study 32146521 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (ULS)
Number of subjects: 374
Study 32146521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 374
Study 32146521 — intervention group
Group type: COMPARATOR
Intervention: Advanced prolapse
Number of subjects: 374
Study 35813030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 0
Study 35813030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33414442 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC210 (300 mg)
Number of subjects: 21
Study 33414442 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC210 (2000 mg)
Number of subjects: 21
Study 33414442 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC210 (200 mg)
Number of subjects: 21
Study 33414442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.5 mg)
Number of subjects: 21
Study 33414442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 33414442 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC210 (low dose)
Number of subjects: 21
Study 32129101 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion with supportive care
Number of subjects: 60
Study 32129101 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 60
Study 34991510 — intervention group
Group type: EXPERIMENTAL
Intervention: AJoM program (classroom-based physical activity breaks) implemented for eight weeks
Number of subjects: 40
Study 34991510 — intervention group
Group type: EXPERIMENTAL
Intervention: AJoM program (classroom-based physical activity breaks)
Number of subjects: 40
Study 33616643 — intervention group
Group type: EXPERIMENTAL
Intervention: Avexitide 30 mg twice daily
Number of subjects: 18
Study 33616643 — intervention group
Group type: EXPERIMENTAL
Intervention: Avexitide 60 mg once daily
Number of subjects: 18
Study 33616643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32421841 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular naloxone hydrochloride (PFS)
Number of subjects: 14
Study 35086184 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcasts and online CR modules
Number of subjects: 48
Study 35086184 — intervention group
Group type: COMPARATOR
Intervention: Pre-established online CR modules
Number of subjects: 48
Study 35086184 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcasts
Number of subjects: 48
Study 35340943 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope (Group GVL, N = 60)
Number of subjects: 120
Study 35340943 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group L, N = 60)
Number of subjects: 120
Study 35340943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 34636520 — intervention group
Group type: EXPERIMENTAL
Intervention: 20U incobotulinumtoxinA (INCO)
Number of subjects: 241
Study 34636520 — intervention group
Group type: EXPERIMENTAL
Intervention: 50U incobotulinumtoxinA (INCO)
Number of subjects: 241
Study 34636520 — intervention group
Group type: EXPERIMENTAL
Intervention: 75U incobotulinumtoxinA (INCO)
Number of subjects: 241
Study 34636520 — intervention group
Group type: EXPERIMENTAL
Intervention: 100U incobotulinumtoxinA (INCO)
Number of subjects: 241
Study 36113856 — intervention group
Group type: EXPERIMENTAL
Intervention: DrySee dressing (DSD)
Number of subjects: 20
Study 36113856 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm + Pad (comparator)
Number of subjects: 20
Study 33104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalike isotonic fluid therapy (140 mmol/L sodium and 5 mmol/L potassium in 5% dextrose)
Number of subjects: 614
Study 33104176 — intervention group
Group type: COMPARATOR
Intervention: Moderately hypotonic fluid therapy (80 mmol/L sodium and 20 mmol/L potassium in 5% dextrose)
Number of subjects: 614
Study 33104176 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalike isotonic fluid therapy
Number of subjects: 614
Study 33104176 — intervention group
Group type: COMPARATOR
Intervention: Moderately hypotonic fluid therapy
Number of subjects: 614
Study 33090505 — intervention group
Group type: EXPERIMENTAL
Intervention: lottery incentive group
Number of subjects: 244
Study 33090505 — intervention group
Group type: COMPARATOR
Intervention: waitlist (delayed incentive) control group
Number of subjects: 244
Study 33527492 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) analysis among diseases using a new conditional network construction approach.
Number of subjects: 100000
Study 33053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg once daily)
Number of subjects: 612
Study 33053283 — intervention group
Group type: COMPARATOR
Intervention: Abatacept (intravenous)
Number of subjects: 612
Study 33053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 612
Study 33053283 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 612
Study 35714312 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg/day
Number of subjects: 319
Study 35714312 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 319
Study 34648003 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized preformed foot orthoses
Number of subjects: 66
Study 34648003 — intervention group
Group type: COMPARATOR
Intervention: Standard flat innersole (sham)
Number of subjects: 66
Study 34857029 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDUS-family intervention with usual care (n = 199)
Number of subjects: 297
Study 34857029 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 98)
Number of subjects: 297
Study 34857029 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDUS-family intervention with usual care
Number of subjects: 297
Study 34857029 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 297
Study 35353097 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS morsels (Test I; n = 10)
Number of subjects: 30
Study 35353097 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS+PRF (Test II; n = 10)
Number of subjects: 30
Study 35353097 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30
Study 35353097 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CPS, CPS+PRF, Control)
Number of subjects: 30
Study 33641816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax
Number of subjects: 0
Study 33641816 — intervention group
Group type: COMPARATOR
Intervention: Damon
Number of subjects: 0
Study 33641816 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 35472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated group (opioid-sparing strategies)
Number of subjects: 217
Study 35472588 — intervention group
Group type: COMPARATOR
Intervention: Intubated group (double-lumen tube intubation)
Number of subjects: 217
Study 35472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intubated group
Number of subjects: 217
Study 35472588 — intervention group
Group type: COMPARATOR
Intervention: Intubated group
Number of subjects: 217
Study 34653526 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 × 5 Gy) followed by surgery 7-10 days after irradiation
Number of subjects: 154
Study 34653526 — intervention group
Group type: COMPARATOR
Intervention: Long interval surgery (surgery 4-5 weeks after irradiation)
Number of subjects: 154
Study 34653526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with downstaging after radiotherapy
Number of subjects: 154
Study 34369683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoren tongdu acupuncture method
Number of subjects: 54
Study 34369683 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic treatment with conventional medication)
Number of subjects: 54
Study 32193052 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise-training (IET) program with educational sessions
Number of subjects: 64
Study 32193052 — intervention group
Group type: COMPARATOR
Intervention: Educational sessions alone (Control Group)
Number of subjects: 64
Study 34864617 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation
Number of subjects: 457
Study 34864617 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood total n-3 fatty acids
Number of subjects: 457
Study 34864617 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total n-3 fatty acids
Number of subjects: 457
Study 34864617 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation
Number of subjects: 457
Study 32404001 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 87
Study 32404001 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87
Study 32404001 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 87
Study 33528288 — intervention group
Group type: EXPERIMENTAL
Intervention: Make Ready Model (MRM)
Number of subjects: 68
Study 33528288 — intervention group
Group type: COMPARATOR
Intervention: Standard Cleaning Model (SCM)
Number of subjects: 68
Study 34569327 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mobile applications for health and parenting information
Number of subjects: 1155
Study 34569327 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of evidence-based and culturally-adapted mobile apps
Number of subjects: 1155
Study 32332265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic-guided group
Number of subjects: 123
Study 32332265 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 123
Study 35813848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy availability (EA) reduced by 25% and 75%
Number of subjects: 0
Study 33120762 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shenling Baizhu Powder
Number of subjects: 270
Study 33120762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 35756420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.02 mg/kg)
Number of subjects: 144
Study 35756420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.02 µg/kg)
Number of subjects: 144
Study 35756420 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 144
Study 33962962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin 100 μg every 6 months (q6mo)
Number of subjects: 378
Study 33962962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin 100 μg q6mo
Number of subjects: 378
Study 33962962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 33349862 — intervention group
Group type: COMPARATOR
Intervention: Romidepsin (RMD) 0.5 mg/m2, 2 mg/m2, 5 mg/m2 (single dose)
Number of subjects: 43
Study 33349862 — intervention group
Group type: COMPARATOR
Intervention: Romidepsin (RMD) 5 mg/m2 (multi-dose)
Number of subjects: 43
Study 34749132 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) with 77 g/day protein for 8 weeks
Number of subjects: 108
Study 34749132 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet (VLCD) with 52 g/day protein for 8 weeks
Number of subjects: 108
Study 34749132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VLCDs
Number of subjects: 108
Study 35916669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic intervention (L. paracasei CNCM I‐1518, L. paracasei CNCM I‐3689, L. rhamnosus CNCM I‐3690, and four yogurt strains)
Number of subjects: 0
Study 35916669 — intervention group
Group type: COMPARATOR
Intervention: Control group (without probiotic intervention)
Number of subjects: 0
Study 35916669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic intervention
Number of subjects: 0
Study 35916669 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0